Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734839 | 1.00 | GRM2 (0.35) | GRM2SCN9ANPC1ESR1MAPT | |
| SCHEMBL13731829 | 0.91 | IKBKB (0.34) | GRM2SCN9AMAPTFPR2 | |
| SCHEMBL13734286 | 0.91 | SCN9A (0.33) | SCN9AFPR2 | |
| SCHEMBL13734289 | 0.91 | SCN9A (0.33) | SCN9AFPR2 | |
| SCHEMBL13732245 | 0.90 | SCN9A (0.30) | SCN9A | |
| SCHEMBL13733585 | 0.90 | SCN9A (0.35) | SCN9AFPR2 | |
| SCHEMBL13732031 | 0.90 | SCN9A (0.37) | SCN9AFPR2 | |
| SCHEMBL15711748 | 0.89 | PDE10A (0.31) | — | |
| SCHEMBL15711839 | 0.89 | PDE10A (0.31) | — | |
| SCHEMBL13732474 | 0.88 | SCN9A (0.31) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | claimed |
| US-9511073-B2 | Aromatic amides and uses thereof | TAXIS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-05-15 | — | — | US | claimed |
| EP-2699557-A1 | AROMATIC AMIDES AND USES THEREOF | Biota Scientific Management Pty Ltd (AU) | 2014-02-26 | — | — | EP | claimed |
| WO-2012142671-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-10-26 | — | — | WO | claimed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | NAT1, ASNS, CYP2C9 | GRM2 4780/4885SCN9A 891/4885NPC1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.